Table 4.

Factors associated with AEFI among the study participants (N = 1826)

Variables	Categories	AEFI yes, N (%)	AEFI no, N (%)	p value	Crude OR (95% CI)	p value	Adjusted OR (95% CI)	p value
Age group	18–29 years	169 (34.6)	319 (65.4)	0.021	1
	30–39 years	132 (31.7)	285 (68.3)		0.87 (0.66–1.15)	0.344
	40–49 years	121 (25.8)	348 (74.2)		0.65 (0.49–0.86)	0.003
	50–59 years	83 (27.5)	219 (72.5)		0.71 (0.52–0.97)	0.037
	≥60 years	39 (26.0)	111 (74.0)		0.66 (0.44–0.99)	0.049
Gender	Male	273 (27.3)	727 (72.7)	0.010	1		1	0.010
	Female	271 (32.8)	555 (67.2)		1.30 (1.06–1.59)	0.010	1.31 (1.07–1.61)
Comorbidity status	No	496 (28.8)	1225 (71.2)	<0.001	1		1	0.200
	Yes	48 (45.7)	57 (54.3)		2.08 (1.39–3.09)	<0.001	1.75 (0.74–4.11)
History of steroid intake	No	534 (29.5)	1275 (70.5)	0.009	1		1	0.535
	Yes	10 (58.8)	7 (41.2)		3.41 (1.29–9.00)	0.013	1.41 (0.47–4.20)
History of taking immunomodulators	No	542 (29.7)	1280 (70.3)	0.587	1
	Yes	2 (50.0)	2 (50.0)		2.36 (0.33–16.80)	0.391
History of allergy	No	531 (29.5)	1269 (70.5)	0.023	1		1	0.373
	Yes	13 (50.0)	13 (50.0)		2.39 (1.10–5.18)	0.028	1.47 (0.62–3.46)
Medication history in last six months for chronic disease	No	505 (29.0)	1236 (71.0)	0.001	1		1	0.869
	Yes	39 (45.9)	46 (54.1)		2.07 (1.33–3.21)	0.001	1.08 (0.43–2.70)
COVID‐19 infection in last 3 months	No	541 (29.7)	1281 (70.3)	0.048	1
	Yes	3 (75.0)	1 (25.0)		7.10 (0.73–68.44)	0.090
Hospital admission in last 3 months	No	541 (29.7)	1281 (70.3)	0.048	1
	Yes	3 (75.0)	1 (25.0)		7.10 (0.73‐68.44)	0.090
Acute infection in last 3 months	No	521 (29.1)	1268 (70.9)	<0.001	1		1	0.001
	Yes	23 (62.2)	14 (37.8)		3.99 (2.04–7.83)	<0.001	3.26 (1.59–6.65)

Abbreviation: AEFI, adverse events following immunization.